Steven Lo
Chief Executive Officer
Mr. Lo is a highly experienced biopharma executive with over 25 years of experience in the healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies.
Prior to Vaxart, Mr. Lo was Chief Executive Officer and a member of the board of directors of Valitor, a private biotech company, from 2022 to 2024. From 2019 to 2022, he was the President, Chief Executive Officer and member of the board of directors of Zosano Pharma. From 2015 to 2019, he was the Chief Commercial Officer at Puma Biotechnology. At that company, he built and led business development and the worldwide commercialization of the company’s first product. Prior to that, he was Chief Commercial Officer of Corcept Therapeutics, where he established the commercial organization to launch the company’s first product. Earlier in his career, he spent 13 years at Genentech in a variety of leadership roles in commercialization and market access.
Mr. Lo obtained a Master’s in Health Administration from the University of Southern California and a B.S. in Microbiology from the University of California, Davis.
Dr. Sean Tucker, Ph.D
Senior Vice President and Chief Scientific Officer
Dr. Sean Tucker is the Founder of Vaxart and has served as its Chief Scientific Officer since February 2010. From March 2004 to February 2010, Sean served as Vice President of Research and Director of Immunology. He has held numerous scientific and engineering roles at various biotechnology companies.
Sean has a BSc. in chemical engineering from the University of Washington, an MSc. in chemical engineering from the University of California, Berkeley, and a Ph.D. in immunology from the University of Washington.
Edward B. Berg
Senior Vice President and General Counsel
Mr. Berg has served in senior legal positions at prominent healthcare companies for most of his more than 30-year career and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals and life sciences. Prior to Vaxart, he served as VP, Deputy General Counsel for BioMarin Pharmaceutical Inc. Mr. Berg previously served as VP Legal and the head attorney supporting Novartis’ biosimilar / complex generic unit, the BioPharm division of Sandoz US. Mr. Berg’s previous roles include Deputy General Counsel, Pharmaceutical Operations for Sanofi-Aventis U.S. and Sanofi NA Pharmaceuticals, and Senior Corporate Counsel, Research & Development, Bristol-Myers Squibb, Inc. He began his career in healthcare as Senior Attorney / Associate Counsel for Merck & Co, Inc. Mr. Berg received a B.A. from Washington University in economics and political science and a law degree from the University of Pennsylvania Law School.
Dr. James F. Cummings
Chief Medical Officer
James Cummings is a Board-Certified Infectious Diseases Physician with a twenty six-year career in the US Army and a proven track record in vaccine, drug and diagnostics development.
James served as Director of the Department of Defense’s Global Emerging Infectious Surveillance and Response System (GEIS), with Bio-surveillance Laboratories in 71 countries, the Director of Translational Medicine & Regulated Activities for the Walter Reed Army Institute of Research (WRAIR), and the Consultant to the Surgeon General for all medical research and development.
Before joining Vaxart, James served as President, Government and Public Health Solutions at ICON GPHS and Vice-President of Clinical Development and Translational Medicine at Novavax.
James has a medical degree from Georgetown University School of Medicine.
Phillip Lee
Chief Financial Officer
Mr. Lee has almost 15 years of strategic finance and advisory experience in the biotechnology industry. During his career, he has helped raise over $1 billion of capital and worked on more than $20 billion of M&A transactions, including partnerships, asset acquisitions, mergers, spin-offs and royalty monetizations.
Prior to Vaxart, Mr. Lee was Chief Financial Officer and Chief Operating Officer at Clover Biopharmaceuticals and Vice President, Finance at 4D Molecular Therapeutics. Mr. Lee began his career as an investment banker and was a founding member of Centerview Partners’ healthcare advisory practice.
Mr. Lee earned dual bachelor’s degrees in Electrical Engineering and Computer Sciences and Business Administration from the University of California, Berkeley.
Raymond D. Stapleton, Jr., Ph.D.
Chief Technology Officer
Dr. Stapleton served as CTO and Executive Vice President at Genocea, working to develop next generation personalized immunotherapies in the forms of vaccines and cell therapies. He joined Genocea in January 2021, bringing more than 20 years of industry experience to the company, having led technical, quality and manufacturing operations at commercial and clinical stage biopharmaceutical companies.
Before that, he served as President and Chief Operating Officer of American Type Culture Collection (ATCC), as well as a member of the Board of Directors of both ATCC and ATCC Global.
Prior to ATCC, Dr. Stapleton worked in senior manufacturing and technical operations roles at Iovance Biotherapeutics, Inc. and Synthetic Biologics, Inc. after spending 15 years in positions of increasing responsibility in Merck and Company’s manufacturing organization.
At Merck, Dr. Stapleton led a complex science, technology, and engineering organization at a manufacturing site responsible for supporting Merck’s $5 billion annual revenue vaccine business.
Dr. Stapleton earned a bachelor’s degree in Biology from Mary Washington College in Fredericksburg, Virginia and received his PhD in Microbial Ecology from the University of Tennessee, Knoxville. He has served as peer reviewer for a half dozen scientific journals, co-authored 17 peer-reviewed manuscripts, and holds multiple patents.
